Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen Seals Two Neurology Deals
by Lisa M. Jarvis
September 16, 2013
| A version of this story appeared in
Volume 91, Issue 37
Biogen Idec is handing over $100 million as part of a six-year neurology drug development pact with Isis Pharmaceuticals. Isis will grant Biogen exclusive rights to use its antisense technology to develop treatments for neurological diseases. The companies will jointly validate disease targets; Isis will be responsible for discovering antisense therapies, and Biogen will take the lead on finding small-molecule and biologic drugs. In a separate neurology drug deal, Biogen and Amicus Therapeutics will develop small molecules targeting the lysosomal enzyme glucocerobrosidase for the treatment of Parkinson’s disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X